eli lilly retatrutide - Search News

Eli Lilly, weight loss

· 2d · on MSN

Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and reinforcing the company's lead in the fast-growing market.

Continue reading

Straight Arrow News on MSN · 2d

Eli Lilly touts strong results of new experimental weight loss drug retatrutide

· 3d · on MSN

Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial

2d

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results